Gardp North America Inc

Nonprofit profile at a glance

EIN
864001361
IRS 990 coverage
2021–2024
Forms available
Form 990 2024
Location
Philadelphia, PA, USA
Phone
2158648175
Rating
66
Verdict
SUPPORTED
Rating confidence
Moderate
Sector
Biomedicine, Bioengineering Research

Official website

Reported finances

Revenue
$162,607
Expenses
$228,109
Assets
$0
Liabilities
$0

Source: IRS Form 990. Selected filing: tax year 2024. Amounts in USD.

Leadership & pay

2 people listed

Highest reported compensation

  • SUBASREE SRINIVASAN (MEDICAL DIRECTOR): $157,934 total reported compensation

Source: IRS Form 990. Selected filing: tax year 2024. Names and roles reflect this filing, not necessarily current officeholders.

Overview

Mission

Gardp na was organized to operate and conduct activities in the united states that contribute to the development of new health technologies to fight against antimicrobial resistance ("amr") and to foster appropriate use and enhance access to such technologies.

What it reported doing in 2024

Gardp na was incorporated in may 2021. Activities to date have included initial organizational matters and kick off of programmatic activities.gardp na has initiated the following, consistent with our business plan:1) initiated fundraising and grant making outreach to support research and development ("r&d") and other programs aimed at combating antimicrobial resistance;2) began raising awareness of and fostering public appreciation and understanding of antimicrobial resistance and associated public health issues among policy makers, the media, and private sector, civil society and governmental bodies, the general public and other relevant stakeholders; raising awareness of the need to invest in r&d and sustainable and equitable access programs in the field of antimicrobial resistance, and advocating for the adoption of policies favorable to such investment in the field of antimicrobial resistance, consistent with gardp na's status under section 501(c)(3) of the code and subject to the applicable limitations and restrictions under the code.3) supported other relevant global or regional initiatives in public health, with a focus on antimicrobial resistance, including cooperation with and facilitation of strategic and collaborative relationships among policymakers, academic and research institutions, diagnostic, pharmaceutical and biotechnology companies, philanthropic institutions, civil society and other organizations, whether local, national, or international.

Operating model

Revenue model
Other-operating. 99% of the money available for current operations came from other operating revenue.
Distribution model
Direct operator. The filing allocates 100% of reported program-service expenses outside its grant, affiliate-payment, and member-benefit lines. This expense classification does not rule out separately announced grant awards.

The verdict

SUPPORTED - A large share of available resources goes toward mission work and the filed numbers largely add up. Some filing-based governance responses are negative or unanswered and expenses are high relative to revenue.

Rating breakdown

  • Financial Efficiency: 67
  • Transparency & Controls: 77
  • Accountability: 79
  • Sustainability: 4
  • Growth: 0

Detailed rating inputs

Financial Efficiency

  • Mission deployment rate: 84.5%; rating input score 84
  • Program expense ratio: 60.2%; rating input score 60
  • Fundraising efficiency: Limited

Transparency & Controls

  • Consistency checks: 100%; rating input score 100; 64th percentile among comparable filings
  • Pay-setting controls: 3 of 6 controls in place; rating input score 50
    • Compensation committee: Missing
    • Independent consultant: Missing
    • Other Form 990s reviewed: Missing
    • Written employment contract: Pass
    • Compensation survey or study: Pass
    • Board or committee approval: Pass
  • Foreign activity oversight: Limited
  • Grant itemization coverage: Limited
  • Major donor itemization: Limited
  • Related-party transparency: Limited

Accountability

  • Independent voting board: 100%; rating input score 100; 63rd percentile among comparable filings
  • Governance controls: 4 of 8 controls in place; rating input score 50
    • Conflict-of-interest policy: Pass
    • Whistleblower policy: Fail
    • Document-retention policy: Fail
    • CEO compensation review process: Pass
    • Other executive compensation review process: NotApplicable
    • Form 990 shared with the board: Pass
    • Board meeting minutes documented: Pass
    • Audit committee oversight: Missing
    • Independent financial-statement audit: Fail

Sustainability

  • Operating margin: -40.3%; rating input score 7; 7th percentile among comparable filings
  • Total-asset coverage ratio: 0; rating input score 1; 1st percentile among comparable filings
  • Liabilities to assets ratio: Limited
  • Officer compensation ratio: 69.2%; rating input score 2; 2nd percentile among comparable filings

Growth

  • Program expense growth: -9.7% per year; rating input score 0; 11th percentile among comparable filings
  • Revenue growth: -79.6% per year; rating input score 0; 0th percentile among comparable filings
  • Asset growth: -85.6% per year; rating input score 0; 0th percentile among comparable filings

Details

  • Where the money goes: 84.5% of revenue deployed · 60.2% of spending went to programs
  • Governance: 1 of 1 board members independent · 4 of 8 filing controls reported
  • Programs: 1 filed program accomplishment · $137K in reported program spending
  • Leadership: top reported pay $158K · 2 people listed · 3 of 6 pay-setting controls reported
  • Consistency: 23 of 23 current checks pass
  • Schedules: 4 filed schedules · includes executive pay
  • Filing history: 4 filing years from 2021 to 2024
  • Contacts: How to reach this organization
  • Money network: 1 filed money-flow record
  • Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
  • People: Everyone the filings name, and which of them the filings identify by more than a name.

Key Signals

Signals prioritize questions for review. They are not findings of misconduct.

  • Review — Accountability: Governance controls: 3 of 7 not reported.
  • High — Sustainability: Operating margin scored 7/100.
  • High — Growth: Program expense growth scored 0/100.
  • High — Growth: Revenue growth scored 0/100.
  • High — Sustainability: Total-asset coverage ratio scored 1/100.
  • High — Growth: Asset growth scored 0/100.
  • High — Sustainability: Officer compensation ratio scored 2/100.